Bridging data science and business strategy
Built on experience with pharmaceutical, medical device, and biotechnology companies from Fortune 500 leaders to emerging firms, our analytics expertise powers regulatory submissions, peer-reviewed publications, and market access strategies that generate real results.
Meet the Founder
Ian Weimer is a healthcare data scientist and Founder of Weimer Analytics, where he helps healthcare organizations translate complex clinical and economic data into evidence that drives payer decisions, regulatory strategy, and market access. His work spans from Fortune 500 pharmaceutical, medical device, and biotechnology companies to emerging firms and mission-driven healthcare organizations, with a focus on turning real-world evidence into compelling financial narratives that resonate with payers and health systems.
Across his career, Ian has led analyses of billions of patient records from claims and EHR databases, developed algorithms that quantify the cost impact of clinical interventions, applied machine learning to identify patient populations most likely to benefit from targeted therapies, and built ROI models that support payer contracting for community health programs. His work has contributed to 16+ peer-reviewed publications and conference presentations and has directly informed pricing strategy, market positioning, and regulatory decision-making. He is known for bridging the gap between analytical rigor and practical business application, making complex findings accessible and actionable for diverse stakeholders.
Selected Publications
A selection of peer-reviewed journal articles and conference research spanning health economics and outcomes research, real-world evidence, and applied machine learning. The complete publication list is available on Google Scholar.
-
Journal Article
Williams SB, Yapici HO, Singhal PK, Weimer I, et al. Real-world economic burden and healthcare resource utilization of radical cystectomy and trimodal therapy for bladder cancer in the United States. Urology. 2025;200:62-69. doi:10.1016/j.urology.2025.03.028
-
Journal Article
Williams SB, Yapici HO, Singhal PK, Weimer I, et al. Real-world study of short-term and long-term clinical outcomes with radical cystectomy for bladder cancer in the United States. JU Open Plus. 2025;3(6):e00057. doi:10.1097/JU9.0000000000000286
-
Journal Article
Obeng-Kusi M, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, et al. Healthcare resource utilization and costs in patients with chronic lymphocytic leukemia or small lymphocytic leukemia treated with covalent Bruton's tyrosine kinase inhibitors: real-world impact of cardiovascular adverse events. Cancer Med. 2025;14(24):e71484. doi:10.1002/cam4.71484
-
Journal Article
Dingli D, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, et al. Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. Future Oncol. 2026;22(1):71-82. doi:10.1080/14796694.2025.2600913
-
Conference Abstract
Viayna E, Ardiles T, Runken MC, Weimer I, et al. Assessing the impact of early albumin administration in patients requiring intravascular resuscitation: application of machine learning techniques to electronic health record (EHR) data. Value Health. 2023;26(6):S278-S279.
-
Conference Abstract
Saasouh W, Zhang X, Weimer I, Hale B, Chappell D. Real-world assessment of the impact of intraoperative hypotension on healthcare resource utilization (HCRU) after elective non-cardiac surgery. Value Health. 2025;28(6):S80.
Have a project where the evidence needs to drive the decision?
Schedule a CallHow We Work
Direct Collaboration
We assemble the right mix of data science, engineering, and clinical expertise, so you work directly with experienced specialists, never handed off to junior staff.
Analytical Rigor
Every analysis is built on careful methodology, validation, and documentation, the standard required for regulatory submissions and peer-reviewed publication. Accuracy is treated as non-negotiable.
Business-Ready Insights
Complex findings translated into clear, compelling narratives that resonate with payers, regulators, and executives, so the analysis actually moves decisions rather than sitting in a report.
Why We Exist
In an industry where data drives everything from drug development to regulatory strategy to patient outcomes, organizations need analytics partners who understand both the science and the business.
We provide that expertise, delivering insights through dedicated collaboration that inform better decisions and drive real impact.
Let's Explore How Data Science Can Advance Your Mission
Ready to transform your data into strategic insights? Schedule a call to discuss your analytics needs.
Schedule a Call